Abstract 382: Risk Prediction Algorithm Accurately Identifies Patients at High Risk for 30-Day Readmission after Percutaneous Coronary Intervention

Author(s):  
Craig E Strauss ◽  
Brandon R Porten ◽  
Denise L Mueller ◽  
Ross F Garberich ◽  
Ivan J Chavez ◽  
...  

Background: Approximately 15% of Medicare patients who undergo percutaneous coronary intervention (PCI) are readmitted to the hospital within 30 days of discharge. A risk prediction algorithm which accurately identifies PCI patients’ risk for readmission may provide an opportunity to implement strategies to optimize care transitions to reduce inpatient readmissions and hospitalization costs in higher risk patients. Methods: We retrospectively applied a published validated 30-day readmission risk prediction algorithm to all PCI cases across three high volume centers within a single health care system between July 1, 2009 and September 30, 2013. Readmission risk scores were calculated and cases were grouped by low- (<6), intermediate- (6-10) and high-risk (≥11). Inpatient readmissions were compared between groups. Based on 4.25-year historical data and mean total variable costs per inpatient readmission, we assessed the impact of reducing the readmission rate by 50% in high-risk patients and 30% in intermediate-risk patients on readmissions per year and annual total variable costs. Results: Among 13,494 PCI cases, 1,237 (9.2%) were high-, 5,846 (43.3%) were intermediate- and 6,411 (47.5%) were low-risk. High-, intermediate- and low-risk groups had significantly different overall readmission rates (19.8% vs. 10.5% vs. 5.4%; p<0.001) (Figure). On average, there were 283 readmissions per year, and the mean total variable costs were $6,530 per inpatient readmission. Reducing readmissions by 50% in high-risk patients and 30% in intermediate-risk patients would reduce 72 inpatient readmissions per year and result in total variable costs savings of $470,160 annually. Conclusions: A risk prediction algorithm accurately identifies PCI patients at highest risk for hospital readmission. This tool may enable providers to implement targeted strategies to reduce 30-day readmissions and hospital costs through transition care conferences, registered nurse telephone contact, early clinical follow-up and care management.

2020 ◽  
Vol 14 ◽  
Author(s):  
Johny Nicolas ◽  
Usman Baber ◽  
Roxana Mehran

A P2Y12 inhibitor-based monotherapy after a short period of dual antiplatelet therapy is emerging as a plausible strategy to decrease bleeding events in high-risk patients receiving dual antiplatelet therapy after percutaneous coronary intervention. Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention (TWILIGHT), a randomized double-blind trial, tested this approach by dropping aspirin at 3 months and continuing with ticagrelor monotherapy for an additional 12 months. The study enrolled 9,006 patients, of whom 7,119 who tolerated 3 months of dual antiplatelet therapy were randomized after 3 months into two arms: ticagrelor plus placebo and ticagrelor plus aspirin. The primary endpoint of interest, Bleeding Academic Research Consortium type 2, 3, or 5 bleeding, occurred less frequently in the experimental arm (HR 0.56; 95% CI [0.45–0.68]; p<0.001), whereas the secondary endpoint of ischemic events was similar between the two arms (HR 0.99; 95% CI [0.78–1.25]). Transition from dual antiplatelet therapy consisting of ticagrelor plus aspirin to ticagrelor-based monotherapy in high-risk patients at 3 months after percutaneous coronary intervention resulted in a lower risk of bleeding events without an increase in risk of death, MI, or stroke.


Perfusion ◽  
2020 ◽  
pp. 026765912095205
Author(s):  
Xue Zhang ◽  
Peng Zhang ◽  
Shicheng Yang ◽  
Wenyuan Li ◽  
Xiuzhen Men ◽  
...  

Background: The aim of this research was to use the Mehran risk score to classify elderly diabetics with coronary heart disease to assess the preventive effect of trimetazidine on contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) in different risk population. Methods: An uncompromised of 760 elderly diabetics that went through PCI were included in this research. The patients were first divided into three groups in the light of MRS: low-risk, moderate-risk, and high-risk group, then randomized into trimetazidine group and the control group respectively. The first endpoint was the amount of CIN, which is described as a rise in serum creatinine levels by ⩾44.2 μmol/L or ⩾25% ratio within 48 or 72 hours after medication. Second endpoint included differences in creatinine clearance rate (CrCl), blood urea nitrogen (BUN), serum creatinine (Scr), cystatin-C (Cys-C), and the incidence of major adverse events after administration. Results: In the three groups, the incidence of CIN in trimetazidine and control group was 5.0% versus 4.9%(χ2 = 0.005, p > 0.05), 8.0% versus 18.0% (χ2 = 7.685, p < 0.05), 10.4% versus 27.1% (χ2 = 4.376, p < 0.05), respectively. The multivariable logistic regression result demonstrated that trimetazidine intervention was a profitable element of CIN in moderate and high-risk groups (OR = 0.294, 95% CI 0.094-0.920, p = 0.035). Conclusion: Our study confirmed that trimetazidine can be considered for preventive treatment of CIN occurrence in elderly diabetics with moderate and high-risk population, while there is no obvious advantage compared with hydration therapy in low-risk patients.


Sign in / Sign up

Export Citation Format

Share Document